SUMMARY INTRODUCTION. Accepted for publication 11 February 2003
|
|
- Ami Skinner
- 6 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2003; 17: doi: /j x A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole J. LABENZ*, K. U. PETERSEN, W. RÖSCHà & H. R. KOELZ *Department of Medicine, Jung-Stilling Hospital, Siegen, Germany; Rheinisch-Westfälische Technische Hochschule, Aachen, Germany; àdepartment of Medicine, Hospital Nordwest, Frankfurt, Germany; Division of Gastroenterology, Department of Internal Medicine, Triemli Hospital, Zürich, Switzerland Accepted for publication 11 February 2003 SUMMARY Background: Pantoprazole is claimed to have a lower potential for drug interaction than other proton pump inhibitors. Aim: To estimate the frequency of adverse events and drug interactions reported to the Food and Drug Administration in patients receiving omeprazole, lansoprazole or pantoprazole. Methods: The study involved a search of the Food and Drug Administration s database for adverse events and drug interactions with omeprazole, lansoprazole or pantoprazole as primary or secondary suspect drug. An estimate of the amount of drug dispensed during the adverse event collection period (from US drug launch) was obtained from the International Medical Statistics health database. Results: Of the suspected drug interactions recorded, vitamin K antagonist interactions, although rare, were the most common. The frequency of vitamin K antagonist interactions was 0.09 per million packages for omeprazole and 0.11 per million packages for lansoprazole and pantoprazole. Interactions with benzodiazepines or phenytoin were even rarer, being reported in less than 10 patients on each proton pump inhibitor. Conclusion: The frequency of reported drug interactions was low for omeprazole, lansoprazole and pantoprazole and vitamin K antagonist interactions were by far the most common. These potentially important drug interactions, although rare, were no less frequent on pantoprazole than on omeprazole or lansoprazole, suggesting a class effect. INTRODUCTION Correspondence to: Dr J. Labenz, Department of Medicine, Jung-Stilling Hospital, Wichernstr. 40, D Siegen, Germany. J.Labenz@t-online.de The high efficacy of proton pump inhibitors in treating acid-related upper gastrointestinal disease has led to their widespread use. In spite of their excellent safety record, the relative safety of different proton pump inhibitors has been widely publicized over the last few years, with particular emphasis on drug drug interactions. 1 9 It has been suggested that pantoprazole is less likely than omeprazole or lansoprazole to interact with other drugs as a result of minor differences in its metabolic profile. 10, 11 In a recent retrospective survey of patient treatment records from US veterans, it was concluded that the co-prescription of omeprazole or lansoprazole with warfarin, clarithromycin or diclofenac led to an increase in adverse events, requirements for care and total costs of care. 12 No data on pantoprazole were presented. As we have not previously perceived relevant interaction problems with any of the proton pump inhibitors, we undertook to assess the safety of Ó 2003 Blackwell Publishing Ltd 1015
2 1016 J. LABENZ et al. pantoprazole in comparison with that of omeprazole and lansoprazole in the clinical setting. Information from a broad database was clearly needed, as many of the recent safety comparisons have been conducted in small groups of healthy volunteers and may not be representative of the patient population at large. The evaluation includes overall adverse event data and interactions with other commonly used drugs, with particular emphasis on anticoagulants, obtained from the Food and Drug Administration (FDA) database since the launch of the proton pump inhibitors in the USA. METHODS Adverse events reported to the US FDA have been made available by the US FDA through the Freedom of Information Act. Prior to October 1997, the data were coded using COSTART AE terminology and stored by the FDA in the Spontaneous Reporting System. From November 1997 onwards, the data were coded using the MedDRA terminology and stored by the FDA in the Adverse Event Reporting System. In order to combine the data from these two systems, each data set was imported into a relational database utilizing the DB Import application with a schema that mirrored the organization of the original data sets. The FDA provided one-to-one mapping from COSTART preferred terms to MedDRA preferred terms. This was necessary to produce summary frequency tables in the MedDRA format. The interface was modified to support consistent selection of suspect status criteria, and the drug selection screen was modified to allow for the selection of drug names from both data sets. The adverse event database, which was used as the source of information, was compiled directly from the files provided by the FDA release, i.e. the National Technical Information Service. All cases that contained the names omeprazole, lansoprazole or pantoprazole as primary suspect, secondary suspect or concomitant medication were identified, and, in particular, information on vitamin K antagonist interactions was assembled from the launch of each proton pump inhibitor in the USA (October 1989 for omeprazole, June 1995 for lansoprazole and February 2000 for pantoprazole) to the most recently available reports (September 2001). We did not include rabeprazole in the search because the number of packages sold worldwide (approximately 24 million in 32 countries) since the US launch in August 1999 was too low for a meaningful analysis. The data obtained represent adverse event reporting frequencies, as opposed to actual overall incidence, as adverse events are not always reported. It is important to note that only serious adverse events were reported to the FDA from outside the USA, whereas adverse events reported within the USA were registered as serious and non-serious. The accumulated patient exposure data are based on the total number of packages of drug delivered to pharmacies or hospitals (world-wide) since the launch of each drug in the USA (source: International Medical Statistics health database). RESULTS The results of the overall data search are reported in Table 1 and represent all FDA reports received after each drug was launched in the USA (1989 for omeprazole, 1995 for lansoprazole and 2000 for pantoprazole). The drug interactions column represents all events reported in the USA in which the Table 1. Adverse events and important interactions reported to the FDA (US and foreign) following the launch of each proton pump inhibitor in the USA PPI Date of US launch Total no. of AEs containing PPI name* Drug interactions where PPI was primary or secondary suspect drug Most common drug interactions AVK Benzodiazepines Phenytoin Omeprazole October Lansoprazole June Pantoprazole February AE, adverse event; AVK, vitamin K antagonist; FDA, Food and Drug Administration; PPI, proton pump inhibitor. * World-wide reports to FDA, including serious AEs from outside USA and serious + non-serious AEs from within USA. PPI and AVK both labelled as either primary or secondary suspect and a bleeding event or blood abnormality in prothrombin time or international normalized ratio reported.
3 SAFETY OF OMEPRAZOLE, LANSOPRAZOLE AND PANTOPRAZOLE 1017 Table 2. World-wide vitamin K antagonist interactions (with bleeding event or blood abnormality) PPI Drug packages supplied world-wide (millions) Interactions with PPI as PS or SS Frequency per package Interactions with PPI as PS or sole co-medication Frequency per package Omeprazole 950.1* per million per million per million per million Lansoprazole 195.4à per million per million per million per million Pantoprazole per million per million PPI, proton pump inhibitor; PS, primary suspect; SS, secondary suspect. * October 1989 to September 2001 (i.e. from US launch). October 1989 to April 1991 (i.e. first 19 months after US launch). à June 1995 to September 2001 (i.e. from US launch). June 1995 to December 1996 (i.e. first 19 months after US launch). February 2000 to September 2001 (i.e. first 19 months after US launch). proton pump inhibitor was the primary or secondary suspected drug, and one of the events was drug interaction in the MedDRA terminology. This covered interactions with all types of drug. Vitamin K antagonist interactions, although uncommon for all three proton pump inhibitors, constituted the most frequent class in each case. The column for vitamin K antagonist interactions contains data in which, firstly, a vitamin K antagonist was present as a concomitant drug, primary suspect or secondary suspect, and, secondly, one of the events was a bleeding event or an abnormality in prothrombin time or international normalized ratio. Interactions with benzodiazepines and phenytoin, although sometimes perceived as a potential problem, were even less common (Table 1). In Table 2, the frequency of drug interactions with vitamin K antagonists is expressed per package of drug following the launch in the USA. In addition, the frequency of drug interactions was calculated for the first 19 months after the US launch of each drug, in order to compare frequencies over the same time period from launch. All cases in which the proton pump inhibitor was the primary suspect in the co-medication and all cases in which the proton pump inhibitor was the sole co-medication are presented. Pantoprazole, as primary suspect drug, was associated with a similar frequency of interactions per dispensed drug package (0.11) as omeprazole (0.08) and the same frequency as lansoprazole. Its interaction frequency as sole co-medication (0.08) was the same as that of omeprazole over the same time interval from launch. DISCUSSION This study provides a comparison of adverse event and interaction data for patients on omeprazole, lansoprazole and pantoprazole, as obtained directly from the FDA database by automated procedures, in order to avoid individual selection bias. The most striking feature of the data is the paucity of events occurring over the time period studied for this widely used class of drug. This confirms the experience of controlled clinical trials and previous adverse event studies which shows that proton pump inhibitors are safe and can be used without safety 7, 13 concerns regarding their potential for interaction. We concentrated in particular on vitamin K antagonist interactions, as these are reported more frequently than all other interactions combined and are also important from a theoretical perspective. 2, 14 A possible interaction between warfarin and omeprazole was first suggested by a single case report of widespread bruising and haematuria when a patient on warfarin started taking omeprazole. 15 A study in healthy men showed no clinically significant influence of omeprazole on the anticoagulation activity of warfarin, i.e. no changes in warfarin dosing were required. 16 The interaction was further studied in patients in an attempt to gauge its frequency in the clinical environment. 17 The effect of 20 mg/day omeprazole on the coagulation time and plasma warfarin concentration was measured in patients receiving continuous therapy with warfarin. Plasma S-warfarin concentrations were not significantly affected by the co-administration of omeprazole in these patients and there was no significant change in the coagulation time. The results presented recently by
4 1018 J. LABENZ et al. McCarthy et al. suggest that gastrointestinal bleeding events in elderly patients are more common in patients taking omeprazole or lansoprazole together with warfarin than in patients taking warfarin alone. 12 The conclusions drawn from these results need to be viewed with caution, however, as the authors may have confused causality with association. For example, it was also observed in the same study that patients taking omeprazole or lansoprazole together with non-steroidal anti-inflammatory drugs (NSAIDs) had more gastrointestinal bleeding events than patients taking NSAIDs alone, with the conclusion that these proton pump inhibitors were in some way responsible for the bleeding events. This seems unlikely, as it has been shown, at least for omeprazole, that it does not change the bioavailability of the NSAIDs diclofenac, naproxen and piroxicam. 18 It seems more likely that omeprazole or lansoprazole was given to these patients because of their bleeding problems during NSAID treatment. The interaction effects of pantoprazole with vitamin K antagonist drugs have been studied for single-dose warfarin and for phenprocoumon in healthy volunteers. 19, 20 In both studies, plasma levels of the drugs remained within the range of bio-equivalence. To our knowledge, no studies have been performed in patients on warfarin therapy, with the exception of a recent study which showed a statistically significant but very small decrease in anticoagulant control in patients receiving various proton pump inhibitors, including pantoprazole, together with warfarin. 21 The authors suggested that the results may have been confounded by the increased age and lower testing frequency in the proton pump inhibitor group compared with controls, making the results inconclusive. Adverse events resulting from suspected vitamin K antagonist interactions were rare for all three proton pump inhibitors in our search, contradicting previous suggestions that pantoprazole is safer than omeprazole and lansoprazole because it has a lower potential for interaction. 1, 2, 11, 22 The results do, however, confirm our view, and that of others, that there is no major clinical problem relating to the co-administration of vitamin K antagonists with proton pump inhibitors. 4, 13, 23, 24 The frequency of adverse events resulting from suspected interactions was found to be very small, and sufficiently similar for all three proton pump inhibitors to suggest that the interaction was either a class effect (rather than being specific to one proton pump inhibitor), or a random coincidence. It seems probable that only an isolated sub-group of predisposed individuals may be at risk from proton pump inhibitor vitamin K antagonist interactions and may require adjustment of their anticoagulant dose. Predispositions could arise from deficiencies in the isoforms of cytochrome P450 (CYP) that predominantly account for the metabolism of the drugs concerned: CYP2C19 for proton pump inhibitors and CYP2C9 for warfarin. Owing to genetic polymorphism, some individuals will show reduced or absent expression of the respective isoforms, 25 and may be classified as slow metabolizers. 3, 26 As a result, warfarin may compete for other enzyme breakdown pathways, such as CYP3A4, which participates in the bio-transformation of omeprazole, lansoprazole and pantoprazole, 3 and is able to contribute to S-warfarin hydroxylation. 27 On the other hand, proton pump inhibitors may inhibit 28 or compete 29 for CYP2C9, the predominant isoform involved in S-warfarin metabolism. As the affinity of the proton pump inhibitors for 2C9 is not high, such interactions are highly unlikely to occur in normal metabolizers, 3 but may prevail at high plasma concentrations. The recently reported interaction of pantoprazole with methotrexate suggests that pantoprazole metabolites may also compete with other drugs for renal elimination. 30 This needs further study. The main conclusion of our study is that interactions of proton pump inhibitors with other drugs, including vitamin K antagonists, are rare and do not constitute a major clinical risk. The finding that pantoprazole was associated with at least as many vitamin K antagonist interactions as omeprazole and lansoprazole, per drug package, suggests that these represent a class effect and negates claims that pantoprazole has fewer interactions than other proton pump inhibitors. It can no longer be considered to be a safer proton pump inhibitor on the basis of inference from results obtained in small numbers of healthy volunteers. ACKNOWLEDGEMENT We would like to thank Dr Madeline Frame for assistance with the preparation of the manuscript. REFERENCES 1 Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton-pump
5 SAFETY OF OMEPRAZOLE, LANSOPRAZOLE AND PANTOPRAZOLE 1019 inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9(4): Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): S Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31(1): Unge P, Andersson T. Drug Interactions with proton pump inhibitors. Drug Saf 1997; 16(3): Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3): Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50: Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39(4): Klotz U. Das Interaktionspotential der Protonenpumpeninhibitoren. Verdauungskrankkheiten, Jahrgang ; 1: S Simon WA, Büdingen C, Fahr S, Kinder B, Koske M. The H+,K+-ATPase inhibitor pantoprazole (BY1023/SK & F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991; 42(2): Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34(6): McCarthy DM, McLaughlin T, Yazdani C, El Serag HB, Griffis DL. Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: a cohort study. Gastroenterology 2002; 122(4)(Suppl. 1): A210, Abstract S Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56(23)(Suppl. 4): S Tanaka E. Clinically important pharmacokinetic drug drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998; 23(6): Ahmad S. Omeprazole warfarin interaction [letter]. South Med J 1991; 84: Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: Unge P, Svedberg L-E, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: Andersson T, Bredberg E, Naesdal I, Wilson I. Lack of drug drug interaction between three different non-steroidal antiinflammatory drugs and omeprazole. Eur J Clin Phamacol 1998; 54: Duursema L, Müller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: Ehrlich A, Fuder H, Hartmann M, et al. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol 1996; 51: Donnellan CF, Dass S, Dunn F, Hull MA. Warfarin anti-coagulation controls in patients taking proton pump inhibitors. Gut 2002; 50(Suppl. 2): A237(Abstract). 22 Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW. Pharmacokinetics and drug interactions relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34(Suppl. 1): S Langman MJS. Which PPI? Gut 2001; 49: Petersen KU. Proton pump inhibitors: what is the merit of the later entries? Leber, Magen, Darm 1997; 27(2): Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002; 3(3): de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: Ngui JS, Chen Q, Shou M, et al. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4 - and 10-hydroxywarfarin. Drug Metab Dispos 2001; 29: Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24: Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: Tröger U. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 2002; 324: 1497.
Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers
Aliment Pharmacol Ther 2002; 16: 1811 1817. doi:10.1046/j.0269-2813.2002.01348.x Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers T. SAITOH*, Y.
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationPharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Aliment Pharmacol Ther 2001; 15: 1563±1569. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole T. ANDERSSON*, K. ROÈ HSS, E.BREDBERG & M. HASSAN-ALIN *Clinical Pharmacology,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationEsomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls ABSTRACT
Original Article 21 Esomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls Kanlayanee Archasantisuk, M.Sc.* Sombat Treeprasertsuk, M.D., M.Sc.** Mayyuree Tantisira, Ph.D.** Arun
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationInteraction of Proton Pump Inhibitors with Cytochromes P450: Consequences for Drug Interactions Urs A. Meyera
YALE JOURNAL OF BIOLOGY AND MEDICINE 69 (1996), pp. 23-29. Copyright 1997. All rights reserved. Interaction of Proton Pump Inhibitors with Cytochromes P45: Consequences for Drug Interactions Urs A. Meyera
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More information3. DRUG PROFILES C H 3 H 3 C CH 3. Fig Structure of clarithromycin Chemical name, molecular weight and CAS number
DRUG PRFILES 3. DRUG PRFILES 3.1. CLARITHRMYCIN H 3 C H C H 3 C 2 H 5 C H 3 H H H 3 C N CH3 H Fig. 3.1. Structure of clarithromycin 3.1.1. Synonym 6--Methylerythromycin 3.1.2. Chemical name, molecular
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationOptimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations
July 2002 Notes Biol. Pharm. Bull. 25(7) 923 927 (2002) 923 Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations Tomoko KITA,
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationAll pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.
OMEPRAZOLE Losec 10mg and 20mg Capsules Acid Pump Inhibitors FORMULATION Each capsule contains Omeprazole 10 mg or 20 mg. PHARMACEUTICAL FORM Omeprazole (LOSEC) capsule 10 mg: hard gelatin capsule with
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine Omeprazole Infusion 40 mg Omeprazole 40 mg for intravenous infusion Presentation Each vial contains a white to off-white lyophilised powder consisting of omeprazole
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More informationSurvey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly
Aliment Pharmacol Ther 1999; 13: 813±817. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly R. BOUTET, M. WILCOCK & I. MACKENZIE 1 Department of
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationNew Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders
...SYMPOSIUM PROCEEDINGS... New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders Based on a presentation by Duane D. Webb, MD, FACG Presentation Summary Gastroesophageal reflux
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More information1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication
Investigation 10mg 1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Blister packs of 14 Solid dose form for oral administration. It
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationNEW ZEALAND DATA SHEET. Each glass vial contains a white lyophilised powder consisting of omeprazole 40 mg, which is intended to be reconstituted.
NEW ZEALAND DATA SHEET OMEZOL IV 1. Product Name Omezol IV, 40 mg, powder for infusion. 2. Qualitative and Quantitative Composition Each vial contains 40 mg of omeprazole lyophilised powder. For the full
More informationTITLE: Proton Pump Inhibitors (PPIs) in Renal Transplant Patients: Evidence for PPI of Choice
TITLE: Proton Pump Inhibitors (PPIs) in Renal Transplant Patients: Evidence for PPI of Choice DATE: 25 August 2008 CONTEXT AND POLICY ISSUES: Gastrointestinal (GI) complications including gastroduodenal
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationPthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs
Evolution of antisecretory agents uthapong Ukarapol, MD. Division of Gastroenterology Chiang Mai University istory 1823- Prout discovered gastric hydrochloric acid 1875- eidenhain and 1893- Golgi identified
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:
M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationNSAIDs Change Package 2017/2018
NSAIDs Change Package 2017/2018 Aim: To Reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care Background A key aim of the Safety in Practice programme is to reduce
More informationEffects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Research Paper www.ijpsonline.com Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males SHUBHA RANI AND HARISH PADH* B. V. Patel Pharmaceutical Education and
More informationIdentifying patients who may benefit from stepping down PPI treatment
CLINICAL AUDIT Identifying patients who may benefit from stepping down PPI treatment Valid to January 2024 bpac nz better medicin e This audit identifies patients who are prescribed the proton pump inhibitor
More informationReview article: similarities and differences among delayed-release proton-pump inhibitor formulations
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 20 24. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations J. R. HORN* & C. W. HOWDEN *Department of Pharmacy,
More informationPharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
Drug Saf (2014) 37:201 211 DOI 10.1007/s40264-014-0144-0 REVIEW ARTICLE Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update Ralph-Steven Wedemeyer Henning Blume Published online:
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationComplications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화
Complications of Proton Pump Inhibitor Therapy Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines for gastroesophageal
More informationOriginal article: EFFECT OF CLOPIDOGREL ON THE HYDROXYLATION AND SULFOXIDATION OF OMEPRAZOLE: A SINGLE DOSE STUDY IN HEALTHY HUMAN VOLUNTEERS
Original article: EFFECT OF CLOPIDOGREL ON THE HYDROXYLATION AND SULFOXIDATION OF OMEPRAZOLE: A SINGLE DOSE STUDY IN HEALTHY HUMAN VOLUNTEERS Lateef Ahmad 1, Zafar Iqbal 2, Shabnam Nazir 3 *, Abad Khan
More informationThe first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit
Community Pharmacy NSAID Gastro-Intestinal Safety Audit Working with Primary Care Commissioning, Strategy and Innovation Directorate The first stop for professional medicines advice www.sps.nhs.uk Community
More informationSTEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES
0090-9556/03/3110-1227 1234$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 10 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1086/1095069 DMD 31:1227 1234, 2003
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET PANZOP RELIEF Pantoprazole 20 mg & 40 mg Gastro-Resistant tablets Presentation Panzop Relief 20 mg tablets are dark yellow, oval, biconvex, enteric coated tablets, with PS2 printed
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationCo-prescribing of warfarin with statins and Proton Pump Inhibitors in elderly Australians
Co-prescribing of warfarin with statins and Proton Pump Inhibitors in elderly Australians This is the peer reviewed author accepted manuscript (post print) version of a published work that appeared in
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationRabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects
Aliment Pharmacol Ther 2003; 17: 1109 1114. doi: 10.1046/j.0269-2813.2003.01573.x Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationInitiation of OAC for Atrial Fibrillation Order Set
For Patients Clinically Unsuitable for DOACs Clinician to consider warfarin for the following indications: Mechanical valve - warfarin is indicated to decrease the risk of thromboembolic complications
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationActive ingredients: Pantoprazole sodium 45.1 mg equivalent to 40 mg Pantoprazole base
Trade name Pantazol Vials for I.V. Injection (infusion) Generic name Pantoprazole sodium sesquihydrate Composition Each l ml re-constituted injectable solution contains: Active ingredients: Pantoprazole
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationFigure 1. Number of spontaneous reports received by Lareb for the NOACs per year for different sources
1.1. Overview of reports on novel oral anticoagulants (NOACs) Introduction Lareb published overviews of reports concerning the novel anticoagulants (NOACs) apixaban (Eliquis ), dabigatran (Pradaxa ) and
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationDepartment of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Turkey 2
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc ph in extensive metabolizer patients with gastroesophageal reflux disease
More informationClinical guideline Published: 13 June 2012 nice.org.uk/guidance/cg141
Acute upper gastrointestinal bleeding in over 16s: management Clinical guideline Published: June 2012 nice.org.uk/guidance/cg141 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAm J Gastroenterol 2010;105:
ACCF/ACG/AHA 2010 Expert Consensus Document Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document
More informationPACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationA Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump Inhibitors in a Kidney Transplant Recipient
Cedarville University DigitalCommons@Cedarville Pharmacy Practice Faculty Publications Department of Pharmacy Practice - A Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationDavid A. Peura 1,5*, Anne Le Moigne 2, Heather Wassel 3 and Charles Pollack 4
Peura et al. BMC Gastroenterology (2018) 18:69 https://doi.org/10.1186/s12876-018-0790-2 RESEARCH ARTICLE Open Access Sustained efficacy following resolution of frequent heartburn with an over-thecounter
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationProton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel
Proton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel Dr.A.K.M. Aminul Hoque Assoc. Prof. of Medicine. Dhaka Medical College. Clopidogrel Metabolism Clopidogrel is an inactive
More informationDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION. One vial contains 40 mg pantoprazole (as pantoprazole sodium sesquihydrate).
a Novartis Company 1. NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 40 mg pantoprazole (as pantoprazole sodium sesquihydrate). 3. PHARMACEUTICAL FORM Powder
More informationIntragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal
More informationConcomitant use of clopidogrel and proton-pump inhibitor: a reality check
Special report Concomitant use of clopidogrel and proton-pump inhibitor: a reality check There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism
More information